Projects

IrsiCaixa is involved in a hundred national and international research projects active each year, funded by both public and private entities.

Keywords

Research group

Researcher

From date

To date

RBD Dimer recombinant protein vaccine against SARS-CoV-2

Project status

Ongoing

Start/End

2021

/

2024

Principal investigator

Marta Ruiz Riol

Julià Blanco Arbués

Christian Brander

Jorge Carrillo Molina

Samandhy Cedeño Briceño

Julia García Prado

Nuria Izquierdo Useros

Tuixent Escribà Bel

Eulalia Grau Segú

Beatriz Mothe Pujadas

Strategic lines

Cancer

Emerging infectious diseases

Financing entity

European Commission

Codi: 101046118
Incorporation of a new subject and new groups to the Consortium of the Centro de Investigación Biomédica en Red M.P. (CIBER)

Project status

Ongoing

Start/End

2022

Principal investigator

Julia García Prado

Javier Martínez-Picado

Participating entities

IrsiCaixa, IGTP

Financing entity

ISCIII
Novel bispecific Trimerbody targeting human 4-1BB and Env for immunotherapy based HIV-1 curative therapeutics

Project status

Ongoing

Start/End

2020

/

2022

Principal investigator

Julia García Prado

Participating entities

IrsiCaixa, Hospital 12 de Octubre research institute
Identification and characterization of T cell protective responses against CoV2. ISCIII COV20/0660

Project status

Ongoing

Start/End

2021

/

2022

Principal investigator

Julia García Prado

Financing entity

Instituto de Salud Carlos III (ISCIII)
SARS-CoV-2 infection among healthcare professionals: demographic characteristics and serological and immune responses related to progression's phenotype

Project status

Ongoing

Start/End

2021

/

2022

Participating entities

Irsicaixa / IGTP/ HUGTIP/ IDIAPJGol

Financing entity

Direcció General de Recerca i Innovació en Salut
Enhancing Tissue-Specific Immune Microenvironments for the Cure of HIV. ETI-CURE “La Caixa” Health Research HR20-00218

Project status

Ongoing

Start/End

2021

/

2024

Principal investigator

Julia García Prado

Participating entities

Irsicaixa / VHIR / Universidad Autónoma de Madrid

Financing entity

ETI-CURE “La Caixa” Health Research
DURVAST: A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors

Project status

Ongoing

Start/End

2017

/

2019

Principal investigator

Javier Martínez-Picado

Participating entities

Spanish Lung Cancer Cooperative Group & IrsiCaixa AIDS Research Institute.

Financing entity

AstraZeneca
Translational study of Inhibitory Receptors in HIV-1 infection: Identification of novel immunotherapeutic targets to reverse T-cell immune exhaustion

Project status

Ongoing

Start/End

2018

/

2020

Principal investigator

Julia García Prado

Participating entities

Institut de Recerca de la Sida IrsiCaixa

Financing entity

Ministry of the Economy, Industry and Competitiveness - Carlos III Health Institute (ISCIII) – FEDER. PI17/00164
Preclinical evaluation of immunoregulatory molecules in combination with latency reactivators for the development of new HIV-1 erradication strategies

Project status

Ongoing

Start/End

2015

/

2018

Principal investigator

Julia García Prado

Financing entity

Ministry of the Economy and Competitiveness - Carlos III Health Institute (ISCIII) - FEDER. PI14/01058
LKR155762 Combine use of vaccines an immune check blockers to boost CTL activity against the reservoir

Project status

Ongoing

Start/End

2017

/

2019

Principal investigator

Julia García Prado

Financing entity

MSD